These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 22451607)

  • 1. Progress for stroke prevention with atrial fibrillation: emergence of alternative oral anticoagulants.
    Katsnelson M; Sacco RL; Moscucci M
    Circulation; 2012 Mar; 125(12):1577-83. PubMed ID: 22451607
    [No Abstract]   [Full Text] [Related]  

  • 2. Novel oral anticoagulants for stroke prevention in atrial fibrillation.
    Taylor J
    Eur Heart J; 2012 Jun; 33(12):1419-20. PubMed ID: 22880211
    [No Abstract]   [Full Text] [Related]  

  • 3. Emerging oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
    Destephan C; Waller AH; Patel RJ; Dhruvakumar S; Mazza V; Gerula C; Maher J; Kaluski E
    Minerva Cardioangiol; 2012 Aug; 60(4):425-31. PubMed ID: 22858920
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New anticoagulants for prevention of stroke in patients with atrial fibrillation.
    Viles-Gonzalez JF; Fuster V; Halperin JL
    J Cardiovasc Electrophysiol; 2011 Aug; 22(8):948-55. PubMed ID: 21668558
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on dabigatran for stroke prevention in atrial fibrillation.
    Henry DM
    Conn Med; 2011 Sep; 75(8):479-83. PubMed ID: 21980679
    [No Abstract]   [Full Text] [Related]  

  • 6. [Dabigatran, a new oral anticoagulant].
    Uchiyama S
    Brain Nerve; 2011 Apr; 63(4):411-5. PubMed ID: 21441645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).
    Pengo V; Crippa L; Falanga A; Finazzi G; Marongiu F; Palareti G; Poli D; Testa S; Tiraferri E; Tosetto A; Tripodi A; Manotti C;
    Thromb Haemost; 2011 Nov; 106(5):868-76. PubMed ID: 21946939
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Place of dabigatran in contemporary pharmacotherapy.
    Gums JG
    Pharmacotherapy; 2011 Apr; 31(4):335-7. PubMed ID: 21449622
    [No Abstract]   [Full Text] [Related]  

  • 9. Twice daily dosing of dabigatran for stroke prevention in atrial fibrillation: a pharmacokinetic justification.
    Clemens A; Haertter S; Friedman J; Brueckmann M; Stangier J; van Ryn J; Lehr T
    Curr Med Res Opin; 2012 Feb; 28(2):195-201. PubMed ID: 22208675
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eligibility of patients with atrial fibrillation for new oral anticoagulants.
    Moubarak G; Badenco N; Dreyfus J; Simion C; Delos Paquet A; Cazeau S; Cador R
    Int J Cardiol; 2013 May; 165(3):573-4. PubMed ID: 23031289
    [No Abstract]   [Full Text] [Related]  

  • 11. Efficacy and safety of dabigatran compared to warfarin in patients with paroxysmal, persistent, and permanent atrial fibrillation: results from the RE-LY (Randomized Evaluation of Long-Term Anticoagulation Therapy) study.
    Flaker G; Ezekowitz M; Yusuf S; Wallentin L; Noack H; Brueckmann M; Reilly P; Hohnloser SH; Connolly S
    J Am Coll Cardiol; 2012 Feb; 59(9):854-5. PubMed ID: 22361407
    [No Abstract]   [Full Text] [Related]  

  • 12. Is it time to abandon warfarin and embrace oral direct thrombin inhibitors to prevent stroke in patients with atrial fibrillation?
    Rahme RJ; Bernstein R; Batjer HH; Bendok BR
    Neurosurgery; 2011 Feb; 68(2):N16-7. PubMed ID: 21654569
    [No Abstract]   [Full Text] [Related]  

  • 13. Stroke prevention in atrial fibrillation.
    Wagenaar P
    Cardiovasc J Afr; 2011; 22(2):105. PubMed ID: 21556458
    [No Abstract]   [Full Text] [Related]  

  • 14. The Food and Drug Administration decision not to approve the 110 mg dose of dabigatran: give us a way out.
    Kowey PR; Naccarelli GV
    Am J Med; 2012 Aug; 125(8):732. PubMed ID: 22608987
    [No Abstract]   [Full Text] [Related]  

  • 15. What do the RE-LY, AVERROES and ROCKET-AF trials tell us for stroke prevention in atrial fibrillation?
    Ahrens I; Lip GY; Peter K
    Thromb Haemost; 2011 Apr; 105(4):574-8. PubMed ID: 21225102
    [No Abstract]   [Full Text] [Related]  

  • 16. Dabigatran in patients with nonvalvular atrial fibrillation.
    Gage L
    J Am Coll Cardiol; 2011 Jul; 58(5):551; author reply 551. PubMed ID: 21777759
    [No Abstract]   [Full Text] [Related]  

  • 17. Reducing the risk for stroke in patients who have atrial fibrillation.
    Garcia DA; Hylek E
    Cardiol Clin; 2008 May; 26(2):267-75, vii. PubMed ID: 18406999
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Newer oral anticoagulants should be used as first-line agents to prevent thromboembolism in patients with atrial fibrillation and risk factors for stroke or thromboembolism.
    Granger CB; Armaganijan LV
    Circulation; 2012 Jan; 125(1):159-64; discussion 164. PubMed ID: 22215890
    [No Abstract]   [Full Text] [Related]  

  • 19. Prevention of venous thromboembolism after major orthopedic surgery: indirect comparison of three new oral anticoagulants.
    Maratea D; Fadda V; Trippoli S; Messori A
    J Thromb Haemost; 2011 Sep; 9(9):1868-70. PubMed ID: 21711443
    [No Abstract]   [Full Text] [Related]  

  • 20. [New anticoagulants: "efficacy and safety" or "efficacy or safety"].
    Pernod G
    J Mal Vasc; 2011 Dec; 36(6):337-8. PubMed ID: 21907510
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.